Lead Product(s) : Xenon,Nitrogen
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nobilis Therapeutics has filed an Investigational New Drug application (IND) with the U.S. Food & Drug Administration (FDA) to initiate a Phase 2b clinical trial of its lead drug candidate NBTX-001 in patients with panic disorder (PD).
Product Name : NBTX-001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 23, 2020
Lead Product(s) : Xenon,Nitrogen
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
